Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat-labile enterotoxins (HLTs) are potent immunomodulatory proteins produced by bacteria such as *Escherichia coli* and *Vibrio cholerae*. They are AB5-type toxins with an A subunit possessing ADP-ribosyltransferase activity and a pentameric B subunit for cell binding. HLTs, especially the heat-labile enterotoxin from *E. coli* (LT), have been extensively studied for their strong adjuvant properties in mucosal vaccines. Mutant forms like mLT or dmLT are engineered to reduce toxicity while retaining adjuvanticity.
HLTs act primarily by increasing intracellular cAMP via activation of adenylate cyclase after binding to ganglioside receptors on host cells. This elevation in cAMP modulates immune responses by enhancing antigen-presenting cell function, promoting B cell differentiation, and inducing Th2 responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat-labile Enterotoxin (HLT).